Iovance Biotherapeutics, Inc. (0JDK.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
At close: 07:08PM BST
| Previous close | 9.47 |
| Open | 9.69 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 9.04 - 10.10 |
| 52-week range | 3.22 - 18.31 |
| Volume | |
| Avg. volume | 53,275 |
| Market cap | 1.238B |
| Beta (5Y monthly) | 0.63 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.30 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksHow to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
GlobeNewswireIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., July 19, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (“Iovance” or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on July 18, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 106,010 shares of Iovance’s common stock to nineteen new, non
ZacksHow to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
© 2024 Yahoo. All rights reserved.